Development and internal validation of a screening tool for chronic prostatitis (S-CP).
Clinical decision rules
Prevalence
Prostatitis
Surveys and questionnaires
Undiagnosed diseases
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
04
07
2023
accepted:
10
08
2023
medline:
23
10
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
We developed a simple self-checkable screening tool for chronic prostatitis (S-CP) and internally validated it to encourage men (in the general population) with possible chronic prostatitis to consult urologists. The expert panel proposed the S-CP, which comprises three domains: Area of pain or discomfort (6 components), accompanying Symptom (6 components), and Trigger for symptom flares (4 components). We employed logistic regression to predict chronic prostatitis prevalence with the S-CP. We evaluated the predictive performance using data from a representative national survey of Japanese men aged 20 to 84. We calculated the optimism-adjusted area under the curve using bootstrapping. We assessed sensitivity/specificity, likelihood ratio, and predictive value for each cutoff of the S-CP. Data were collected for 5,010 men-71 (1.4%) had a chronic prostatitis diagnosis. The apparent and adjusted area under the curve for the S-CP was 0.765 [95% confidence interval (CI) 0.702, 0.829] and 0.761 (0.696, 0.819), respectively. When the cutoff was two of the three domains being positive, sensitivity and specificity were 62.0% (95% CI 49.7, 73.2) and 85.4% (95% CI 84.4, 86.4), respectively. The positive/negative likelihood ratios were 4.2 (95% CI 3.5, 5.2) and 0.45 (95% CI 0.33, 0.60), respectively. The positive/negative predictive values were 5.7 (95% CI 4.2, 7.6) and 99.4 (95% CI 99.1, 99.6), respectively. The reasonable predictive performance of the S-CP indicated that patients (in the general population) with chronic prostatitis were screened as a first step. Further research would develop another tool for diagnostic support in actual clinical settings.
Identifiants
pubmed: 37712967
doi: 10.1007/s00345-023-04574-x
pii: 10.1007/s00345-023-04574-x
pmc: PMC10582131
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2759-2765Informations de copyright
© 2023. The Author(s).
Références
J Clin Epidemiol. 2021 Apr;132:88-96
pubmed: 33307188
J Urol. 2013 Jan;189(1):141-5
pubmed: 23164386
Eur Urol. 2016 Feb;69(2):286-97
pubmed: 26411805
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):785-790
pubmed: 35752656
Andrologia. 2021 Nov;53(10):e14206
pubmed: 34365673
Int J Technol Assess Health Care. 1986;2(1):53-63
pubmed: 10300718
World J Urol. 2013 Aug;31(4):755-60
pubmed: 23588814
J Urol. 2005 Dec;174(6):2319-22
pubmed: 16280832
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Clin Epidemiol. 2001 Aug;54(8):774-81
pubmed: 11470385
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
J Urol. 2009 Aug;182(2):558-63
pubmed: 19524948
BJU Int. 2020 Apr;125(4):479-480
pubmed: 32250053
J Urol. 1999 Aug;162(2):369-75
pubmed: 10411041
J Urol. 2001 Mar;165(3):842-5
pubmed: 11176483
J Urol. 2019 Sep;202(3):546-551
pubmed: 30916629
BJU Int. 2015 Oct;116(4):509-25
pubmed: 25711488
Int J Urol. 2003 Dec;10(12):636-42
pubmed: 14633066
Prostate Cancer Prostatic Dis. 2009;12(3):288-95
pubmed: 19350050
J Urol. 2004 Jan;171(1):279-83
pubmed: 14665894
Curr Urol Rep. 2007 Jul;8(4):336-9
pubmed: 18519019